Top 5 Takeaways on SGLT2 Inhibitors From AHA 2020 

Top 5 Takeaways on sodium-glucose cotransporter 2 (SGLT2) Inhibitors From AHA 2020  is organized by Medscape, LLC.

CME / ABIM MOC / CE Released: 12/22/2020
Valid for credit through: 12/22/2021

Accreditation:
For Physicians
Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

For Pharmacists
Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number: JA0007105-0000-20-431-H01-P).

Goal Statement:
The goal of this activity is to educate clinicians about updates and new data in cardiovascular (CV) protection in type 2 diabetes (T2D) presented at the 2020 American Heart Association (AHA) Scientific Sessions.

Learning Objectives:
Upon completion of this activity, participants will:
• Have increased knowledge regarding the
? Role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with T2D and heart failure (HF)
? New data presented at AHA 2020 on the use of SGLT2 inhibitors in patients with T2D and HF